<div id="readability-page-1"><p>ARS Wealth Advisors Group LLC raised its stake in  Merck &amp; Co., Inc. (NYSE:MRK - Free Report) by 3.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 160,088 shares of the company's stock after buying an additional 4,848 shares during the period. Merck &amp; Co., Inc. comprises  2.0% of ARS Wealth Advisors Group LLC's holdings, making the stock its 21st biggest holding. ARS Wealth Advisors Group LLC's holdings in Merck &amp; Co., Inc. were worth $14,370,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><div><p><span></span><span>Get <strong>Merck &amp; Co., Inc.</strong> alerts:</span></p></div><ul><li>Moderna  Stock Looks Ripe for a Short Squeeze</li></ul><p>Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of  Merck &amp; Co., Inc. by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 251,096,107 shares of the company's stock worth $24,979,041,000 after acquiring an additional 1,292,192 shares in the last quarter.  Wellington Management Group LLP raised its stake in shares of  Merck &amp; Co., Inc. by 6.5% during the 4th quarter. Wellington Management Group LLP now owns 80,742,030 shares of the company's stock worth $8,032,217,000 after acquiring an additional 4,932,647 shares in the last quarter.  Geode Capital Management LLC raised its stake in shares of  Merck &amp; Co., Inc. by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 61,181,863 shares of the company's stock worth $6,072,582,000 after acquiring an additional 2,026,859 shares in the last quarter.  Norges Bank bought a new position in shares of  Merck &amp; Co., Inc. during the 4th quarter worth approximately $3,479,799,000.  Finally, Northern Trust Corp raised its stake in shares of  Merck &amp; Co., Inc. by 16.8% during the 4th quarter. Northern Trust Corp now owns 31,377,107 shares of the company's stock worth $3,121,395,000 after acquiring an additional 4,511,742 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors. </p><h2>Insider Buying and Selling</h2><p>In related news, SVP Dalton E. Smart III sold 4,262 shares of the stock in a transaction on Friday, April 25th. The shares were sold at an average price of $82.76, for a total transaction of $352,723.12. Following the sale, the senior vice president now directly owns 7,778 shares of the company's stock, valued at approximately $643,707.28. This represents a 35.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by insiders. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares</li></ul><p>MRK has been the subject of several recent analyst reports. Wall Street Zen lowered shares of Merck &amp; Co., Inc. from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Friday, April 25th. TD Securities lowered shares of Merck &amp; Co., Inc. from a &#34;buy&#34; rating to a &#34;hold&#34; rating and cut their price target for the company from $121.00 to $100.00 in a research note on Monday, February 10th. Cantor Fitzgerald lowered shares of Merck &amp; Co., Inc. from an &#34;overweight&#34; rating to a &#34;cautious&#34; rating in a research note on Tuesday, May 20th. TD Cowen lowered shares of Merck &amp; Co., Inc. from a &#34;buy&#34; rating to a &#34;hold&#34; rating and cut their price target for the company from $121.00 to $100.00 in a research note on Monday, February 10th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Merck &amp; Co., Inc. from a &#34;buy&#34; rating to a &#34;hold&#34; rating and cut their price target for the company from $128.00 to $105.00 in a research note on Tuesday, February 18th. One analyst  has rated the stock with a sell rating, twelve have issued  a hold rating, seven have assigned  a buy rating and two have issued  a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and an average target price of $109.19.</p><p><b>Read Our Latest Research Report on MRK</b></p><h2>Merck &amp; Co., Inc. Stock Up 1.7%</h2><ul><li>Institutional Investors Bet $1B on These 4 Stocks—Should You?</li></ul><p>NYSE:MRK opened at $78.95 on Friday. The firm has a market capitalization of $198.25 billion, a P/E ratio of 11.73, a PEG ratio of 0.77 and a beta of 0.38. Merck &amp; Co., Inc. has a 1-year low of $73.31 and a 1-year high of $134.63. The company's fifty day moving average price is $79.13 and its 200-day moving average price is $89.91. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. </p><p>Merck &amp; Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, topping analysts' consensus estimates of $2.16 by $0.06. The firm had revenue of $15.53 billion for the quarter, compared to analyst estimates of $15.59 billion. Merck &amp; Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The business's quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.07 earnings per share.  As a group, equities research analysts anticipate that  Merck &amp; Co., Inc. will post 9.01 EPS for the current year. </p><h2>Merck &amp; Co., Inc. Announces Dividend</h2><p>The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 8th. Investors of record on Monday, June 16th will be issued a dividend of $0.81 per share. This represents a $3.24 dividend on an annualized basis and a yield of 4.10%. The ex-dividend date of this dividend is Monday, June 16th. Merck &amp; Co., Inc.'s dividend payout ratio (DPR) is presently 47.16%. </p><h2>About Merck &amp; Co., Inc.</h2> (Free Report)<p>Merck &amp; Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.</p><h2>Read More</h2><ul><li>Five stocks we like better than Merck &amp; Co., Inc.</li><li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li><li>X: 1 Reason to Bet on U.S. Steel, and 1 Reason to Hold Back</li><li>Most active stocks: Dollar volume vs share volume</li><li>3 Oversold Stocks Flashing Bullish Reversal Signals</li><li>How to find penny stocks to invest and trade </li><li>With Novo Nordisk's CEO Out, Wall Street Wants an American Leader</li></ul><p><strong>Want to see what other hedge funds are holding MRK?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck &amp; Co., Inc. (NYSE:MRK - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Merck &amp; Co., Inc. Right Now?</h2><p>Before you consider Merck &amp; Co., Inc., you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck &amp; Co., Inc. wasn't on the list.</p><p>While Merck &amp; Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>ARS Wealth Advisors Group LLC increased its stake in Merck & Co., Inc. (NYSE:MRK) by 3.1% in Q1, now holding 160,088 shares valued at $14.37 million. Other investors like Vanguard and Wellington Management also raised their stakes. Insider selling occurred with SVP Dalton E. Smart III selling 4,262 shares. Analyst ratings for MRK have been downgraded by several firms, with an average rating of "Hold" and a target price of $109.19. Merck's stock opened at $78.95, with a market cap of $198.25 billion.</p>

ARS Wealth Advisors Group LLC Grows Stock Holdings in Merck & Co., Inc. (NYSE:MRK)